AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16935583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.02% for 30 seconds
Number of subjects: 9
Study 16935583 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 9
Study 12707658 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback rehabilitation training method (30 minutes daily for 10 months)
Number of subjects: 27
Study 12707658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 10751250 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain MR diffusion histogram analysis in MS patients
Number of subjects: 25
Study 10751250 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain MR diffusion histogram analysis in secondary progressive MS patients
Number of subjects: 25
Study 10751250 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain MR diffusion histogram analysis in relapsing-remitting MS patients
Number of subjects: 25
Study 10751250 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 25
Study 8616659 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicose veins
Number of subjects: 14
Study 8616659 — intervention group
Group type: COMPARATOR
Intervention: Control veins
Number of subjects: 14
Study 8616659 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicose veins proximally
Number of subjects: 14
Study 8616659 — intervention group
Group type: COMPARATOR
Intervention: Control veins proximally
Number of subjects: 14
Study 1419007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg and IM saline
Number of subjects: 20
Study 1419007 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline and IM morphine
Number of subjects: 20
Study 3907678 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 400 mg daily for 48 h followed by 200 mg daily
Number of subjects: 33
Study 3907678 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 800 mg daily for 48 h followed by 400 mg daily
Number of subjects: 33
Study 31045423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Stress Management (CBSM)
Number of subjects: 192
Study 31045423 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion (HP) attention-matched control
Number of subjects: 192
Study 28214040 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g/d AX (n=16)
Number of subjects: 47
Study 28214040 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/d AX (n=17)
Number of subjects: 47
Study 28214040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 47
Study 26962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex protein biochip comprising 120 biomarkers
Number of subjects: 105
Study 26962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CA19‐9, CA15‐3, and kallikrein‐12
Number of subjects: 105
Study 26962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin‐B in isolation
Number of subjects: 105
Study 26962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin‐B with respect to patient's age
Number of subjects: 105
Study 26962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Panels of 4 biomarkers (MMP‐9, cathepsin‐B, C‐reactive protein, chondroitin sulfate)
Number of subjects: 105
Study 26962828 — intervention group
Group type: EXPERIMENTAL
Intervention: Panels of 3 biomarkers (CA19‐9, CA15‐3, kallikrein‐12)
Number of subjects: 105
Study 25315207 — intervention group
Group type: EXPERIMENTAL
Intervention: One scripted telephone call from a diabetes educator or clinical pharmacist
Number of subjects: 2378
Study 25315207 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2378
Study 22353593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 340
Study 22353593 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (control)
Number of subjects: 340
Study 21258306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic seawater solution
Number of subjects: 60
Study 21258306 — intervention group
Group type: COMPARATOR
Intervention: Isotonic seawater solution
Number of subjects: 60
Study 17628197 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees lateral positioning
Number of subjects: 34
Study 16277690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic view
Number of subjects: 50
Study 16277690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip AP view
Number of subjects: 50
Study 16277690 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique view
Number of subjects: 50
Study 12062147 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual bias against the onsets [bw] and [dl] in Experiment 1
Number of subjects: 32
Study 12062147 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual bias against [dl] in CCV and VCCV contexts in Experiment 2
Number of subjects: 32
Study 9534100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 9534100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 7645538 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Epoetin alfa (SC) three times per week
Number of subjects: 72
Study 7645538 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Epoetin alfa (SC) once per week (n = 20)
Number of subjects: 72
Study 7645538 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Epoetin alfa (SC) diluted 1:2 with bacteriostatic saline (n = 23)
Number of subjects: 72
Study 7645538 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Epoetin alfa (SC) three times per week (n = 24)
Number of subjects: 72
Study 2482270 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct immersion in diethylether and ethanol (1:1 v/v)
Number of subjects: 21
Study 2482270 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray fixation (Vale Smear Fix)
Number of subjects: 21
Study 2482270 — intervention group
Group type: EXPERIMENTAL
Intervention: Air drying
Number of subjects: 21
Study 688892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg, hyoscine-N-butylbromide 20 mg, and diazepam 5 mg (Group I)
Number of subjects: 100
Study 688892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine-N-butylbromide 20 mg and diazepam 5 mg (Group II)
Number of subjects: 100
Study 688892 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg and glucagon 0.2 mg (Group III)
Number of subjects: 100
Study 688892 — intervention group
Group type: COMPARATOR
Intervention: Only diazepam 5 mg intravenously (Group IV)
Number of subjects: 100
Study 31807989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose regimen
Number of subjects: 492
Study 31807989 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized regimen
Number of subjects: 492
Study 31807989 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 492
Study 31017657 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.8 mg/kg (40 mg maximum) every other week
Number of subjects: 114
Study 31017657 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.4 mg/kg (20 mg maximum) every other week
Number of subjects: 114
Study 31017657 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 0.1-0.4 mg/kg (25 mg maximum) weekly
Number of subjects: 114
Study 27428678 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill Running (DR)
Number of subjects: 20
Study 27428678 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Resistance Exercise (RE)
Number of subjects: 20
Study 27428678 — intervention group
Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 20
Study 25769363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (635 nm), treated twice a week for 3 weeks (total of 6 treatments)
Number of subjects: 69
Study 25769363 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 69
Study 23549491 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCr‐EES
Number of subjects: 300
Study 23549491 — intervention group
Group type: COMPARATOR
Intervention: PtCr‐EES
Number of subjects: 300
Study 22194126 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTX‐A (Chinese botulinum toxin type A)
Number of subjects: 273
Study 22194126 — intervention group
Group type: COMPARATOR
Intervention: Botox (current formulation)
Number of subjects: 273
Study 22194126 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTX‐A
Number of subjects: 273
Study 22194126 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 273
Study 19539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus an illness perception intervention (three half-hour patient sessions and one half-hour patient-and-spouse session)
Number of subjects: 103
Study 19539814 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 103
Study 19539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus an illness perception intervention
Number of subjects: 103
Study 16938126 — intervention group
Group type: COMPARATOR
Intervention: PZ levels below the 5.0 percentile (0.52 microg mL‐1)
Number of subjects: 197
Study 16938126 — intervention group
Group type: COMPARATOR
Intervention: PZ levels below the 2.5 percentile (0.47 microg mL‐1)
Number of subjects: 197
Study 15491435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (75 mg)
Number of subjects: 47
Study 15491435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 15491435 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE test for food allergy
Number of subjects: 47
Study 11131270 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker treatment during the study
Number of subjects: 95
Study 9303862 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 1000
Study 9303862 — intervention group
Group type: COMPARATOR
Intervention: tPA (anterior AMI) and streptokinase (non-anterior AMI)
Number of subjects: 1000
Study 8519378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-methacholine FEV1 manoeuvre
Number of subjects: 19
Study 8519378 — intervention group
Group type: COMPARATOR
Intervention: No pre-methacholine FEV1 manoeuvre
Number of subjects: 19
Study 8519378 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened time interval between dose steps (3 min)
Number of subjects: 19
Study 3302270 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter-inducing audio tape
Number of subjects: 60
Study 3302270 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-inducing audio tape
Number of subjects: 60
Study 3302270 — intervention group
Group type: COMPARATOR
Intervention: Dull-narrative audio tape
Number of subjects: 60
Study 3302270 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 60
Study 3302270 — intervention group
Group type: COMPARATOR
Intervention: Interesting narrative audio tape
Number of subjects: 60
Study 3302270 — intervention group
Group type: COMPARATOR
Intervention: Uninteresting narrative audio tape
Number of subjects: 60
Study 3302270 — intervention group
Group type: COMPARATOR
Intervention: Multiplication task
Number of subjects: 60
Study 3302270 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study 30718539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rTMS and ABM training
Number of subjects: 72
Study 30718539 — intervention group
Group type: COMPARATOR
Intervention: rTMS alone
Number of subjects: 72
Study 30718539 — intervention group
Group type: COMPARATOR
Intervention: ABM treatment
Number of subjects: 72
Study 30718539 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 72
Study 30324926 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) eyeglasses
Number of subjects: 40
Study 30324926 — intervention group
Group type: COMPARATOR
Intervention: No VR eyeglasses (Control)
Number of subjects: 40
Study 27561000 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone‐iodine applied at the end of surgery
Number of subjects: 65
Study 27561000 — intervention group
Group type: COMPARATOR
Intervention: No povidone‐iodine (control group)
Number of subjects: 65
Study 27561000 — intervention group
Group type: COMPARATOR
Intervention: No povidone‐iodine (group 2)
Number of subjects: 65
Study 27561000 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone‐iodine
Number of subjects: 65
Study 23557912 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised Corrected Feedback (ICF)
Number of subjects: 104
Study 23557912 — intervention group
Group type: COMPARATOR
Intervention: Consent as Usual (CAU)
Number of subjects: 104
Study 22178084 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 285
Study 22178084 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg
Number of subjects: 285
Study 22178084 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Number of subjects: 285
Study 22178084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 20453263 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnsons Top‐to‐Toe cleanser (JTT)
Number of subjects: 180
Study 20453263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebamed Baby Liquid cleanser (SM)
Number of subjects: 180
Study 20453263 — intervention group
Group type: COMPARATOR
Intervention: Lukewarm tap water
Number of subjects: 180
Study 17364399 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patient-caregiver relationship quality
Number of subjects: 176
Study 17364399 — intervention group
Group type: COMPARATOR
Intervention: Caregiver depression
Number of subjects: 176
Study 17364399 — intervention group
Group type: COMPARATOR
Intervention: Caregiver burden
Number of subjects: 176
Study 17364399 — intervention group
Group type: COMPARATOR
Intervention: HIV patient depression
Number of subjects: 176
Study 17364399 — intervention group
Group type: COMPARATOR
Intervention: Physical functioning
Number of subjects: 176
Study 17364399 — intervention group
Group type: COMPARATOR
Intervention: HIV medication adherence
Number of subjects: 176
Study 16289803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for chronic pain
Number of subjects: 78
Study 12109952 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (5 mg bolus injections at 5 min intervals)
Number of subjects: 10
Study 12109952 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine
Number of subjects: 10
Study 12109952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 10
Study 10546840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (3.2‐mg/kg loading dose followed by 1.6 mg/kg daily)
Number of subjects: 103
Study 10546840 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (20‐mg/kg loading dose followed by 10 mg/kg every 8 h)
Number of subjects: 103
Study 8696533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (group B, n = 21)
Number of subjects: 95
Study 8696533 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering treatment (group C, n = 22)
Number of subjects: 95
Study 8696533 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A, n = 52)
Number of subjects: 95
Study 8696533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (group B)
Number of subjects: 95
Study 8696533 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering treatment (group C)
Number of subjects: 95
Study 1978497 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride 100-300 mg/day (n = 60)
Number of subjects: 186
Study 1978497 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride 200-600 mg/day (n = 61)
Number of subjects: 186
Study 1978497 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10-30 mg/day (n = 64)
Number of subjects: 186
Study 351394 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 585
Study 351394 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (Men)
Number of subjects: 585
Study 351394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 585
Study 351394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aspirin and Sulfinpyrazone
Number of subjects: 585
Study 31694579 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with polypectomy/endoscopic mucosal resection
Number of subjects: 236
Study 31694579 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy without prophylactic antibiotics
Number of subjects: 236
Study 27696468 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsive Exercise Test (CET)
Number of subjects: 78
Study 27696468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination (EDE)
Number of subjects: 78
Study 27696468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination-Questionnaire (EDE-Q)
Number of subjects: 78
Study 27696468 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise time per day
Number of subjects: 78
Study 27696468 — intervention group
Group type: EXPERIMENTAL
Intervention: EDE exercise days
Number of subjects: 78
Study 26267731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0, then 40 mg every other week starting at week 1)
Number of subjects: 0
Study 26267731 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (up to 25 mg/week orally)
Number of subjects: 0
Study 26267731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26267731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 23730899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (SPACE intervention)
Number of subjects: 1348
Study 23730899 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison schools)
Number of subjects: 1348
Study 21331473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-dissolving azithromycin gelatin capsules
Number of subjects: 0
Study 21331473 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC capsules
Number of subjects: 0
Study 21331473 — intervention group
Group type: COMPARATOR
Intervention: Commercial azithromycin gelatin capsules
Number of subjects: 0
Study 19705104 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 17
Study 19705104 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 17
Study 16983108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 every 3 weeks
Number of subjects: 571
Study 16983108 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 571
Study 15090933 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg bid)
Number of subjects: 16
Study 15090933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11561264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 66
Study 11561264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 66
Study 11561264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 66
Study 9745057 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 40
Study 9745057 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 40
Study 8148228 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (10 mg)
Number of subjects: 0
Study 8148228 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (4 mg)
Number of subjects: 0
Study 8148228 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 0
Study 2844548 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 500 micrograms/day
Number of subjects: 16
Study 2844548 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1000 micrograms/day
Number of subjects: 16
Study 2844548 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2000 micrograms/day
Number of subjects: 16
Study 2844548 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) (all doses)
Number of subjects: 16
Study 29700575 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + aflibercept
Number of subjects: 918
Study 29700575 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 918
Study 28985270 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium intake (150 mmol/day)
Number of subjects: 0
Study 28985270 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary sodium intake (200-250 mmol/day)
Number of subjects: 0
Study 28985270 — intervention group
Group type: COMPARATOR
Intervention: Low dietary sodium intake (60 mmol/day)
Number of subjects: 0
Study 25058329 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physical activity (PA) increase
Number of subjects: 150
Study 25058329 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in sedentary time
Number of subjects: 150
Study 23190286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 211
Study 23190286 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 211
Study 23190286 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 211
Study 23190286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study 21386999 — intervention group
Group type: COMPARATOR
Intervention: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in dyskinetic PD patients
Number of subjects: 22
Study 21386999 — intervention group
Group type: COMPARATOR
Intervention: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in drug-naïve PD patients
Number of subjects: 22
Study 21386999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET after antiparkinsonian therapy in drug-naïve PD patients
Number of subjects: 22
Study 18200673 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL/d of 20% alanyl-glutamine dipeptide (AGD) intravenously for 10 days (early treatment group)
Number of subjects: 80